|
Daily Medical Update
Bronchiectasis
Thursday, September 24, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Cell reports. Medicine (2026) - Randomized Controlled Trial
Key Findings
- Florensocatib reduced exacerbation rates versus placebo (RR 0.47, 95% CI 0.33-0.67), with similar direction of effect in high-symptom (RR 0.53) and low-symptom (RR 0.40) groups.
- Inhaled tobramycin produced clinically meaningful QoL-B-RSS improvement above the 8-point threshold in patients with high baseline symptom burden and improved bronchitic symptoms.
📋 Practice Implication: Baseline symptom burden may help match therapy to the dominant treatment goal: florensocatib for exacerbation reduction and inhaled tobramycin for symptom relief in highly symptomatic patients.
|
The European respiratory journal (2025) - Practice Guideline
Key Findings
- Airway-clearance techniques were strongly recommended for most adults, and pulmonary rehabilitation was strongly recommended for patients with impaired exercise capacity to improve functional outcomes.
- Long-term macrolides were strongly recommended to reduce exacerbation risk in high-risk patients, while long-term inhaled antibiotics were strongly recommended for chronic Pseudomonas aeruginosa infection with high exacerbation risk; routine inhaled corticosteroids and long-term non-macrolide oral antibiotics were not recommended.
📋 Practice Implication: Use the ERS framework to anchor routine care in airway clearance and rehabilitation, reserving prolonged antimicrobial strategies for defined exacerbation-risk or Pseudomonas phenotypes.
|
European respiratory review : an official journal of the European Respiratory Society (2026) - Systematic Review/Meta-Analysis
Key Findings
- Pooled analysis did not significantly reduce annualized exacerbations (mean difference -0.40 per patient-year, 95% CI -1.04 to 0.24; p=0.22).
- FEV1 percent predicted increased by a small mean 3.23% (95% CI 0.31-6.15; p=0.03), while pooled quality-of-life, other spirometry, and adverse-event outcomes did not differ significantly.
📋 Practice Implication: Routine mucoactive prescribing should remain individualized because the pooled exacerbation benefit was not significant and the small lung-function signal came from low-certainty evidence.
|
International journal of antimicrobial agents (2026) - Meta-Analysis/Review
Key Findings
- In non-cystic-fibrosis bronchiectasis, inhaled antibiotics likely reduced exacerbation frequency (RR 0.86, 95% CI 0.78-0.96).
- They likely improved microbiological eradication (RR 2.16, 95% CI 1.21-3.86) but increased bronchospasm (RR 1.43, 95% CI 1.05-1.96) and antibiotic resistance (RR 1.97, 95% CI 1.55-2.49).
📋 Practice Implication: Inhaled antibiotics can be useful for selected non-CF bronchiectasis patients, but treatment decisions should include airway-reactivity monitoring and antimicrobial-resistance stewardship.
|
The New England journal of medicine (2025) - Randomized Controlled Trial
Key Findings
- Hypertonic saline did not significantly reduce mean 52-week exacerbations versus no hypertonic saline (0.76 vs 0.98; adjusted difference -0.25, 95% CI -0.57 to 0.07; p=0.12).
- Carbocisteine also did not significantly reduce exacerbations (0.86 vs 0.90; adjusted difference -0.04, 95% CI -0.36 to 0.28; p=0.81), and secondary outcomes and adverse events were similar.
📋 Practice Implication: For patients already receiving standard care, neither hypertonic saline nor carbocisteine should be expected to lower exacerbation rates reliably without a clear individual symptom or sputum-management rationale.
|
|
💡
Summary
Recent bronchiectasis evidence supports a phenotype- and risk-based approach: florensocatib reduced exacerbations across symptom strata, while inhaled tobramycin improved symptoms mainly in patients with higher baseline burden. Guidelines prioritize airway clearance, pulmonary rehabilitation when exercise capacity is impaired, and targeted macrolide or inhaled-antibiotic therapy for high-risk groups; meta-analytic data support inhaled antibiotics in non-CF bronchiectasis but also show bronchospasm and antibiotic-resistance risks. Mucoactive-agent evidence is less persuasive, with no significant exacerbation reduction in pooled analyses or in a large hypertonic saline/carbocisteine trial.
|
|